Medical Necessity Documentation:
Client Notes:
Order must include the reason for testing and a current CBC report and a stained peripheral blood slide
Patient Preparation:
Anti-leukemic drug therapy may suppress cell division. The patient should not have received these drugs within 6 weeks of sample collection.
Specimen Requirements:
3.0 mL Bone Marrow in a Green Top Tube - Na Heparin
Collection Instructions:
Bone Marrow must contain 10% less mature myelocytes, pros or blasts
Clinical history/reason for referral is required with test order. Previous bone marrow transplant or therapy information, if applicable, should be provided with test order.
Minimum Volume:
2.0 mL Bone Marrow
Neonatal Volume:
Infants: 2-3 mL (pediatric 3mL vacutainer)
Transport & Storage: Temperature/Stability:
Ambient (Transport)
Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination.
Rejection Criteria:
Frozen
Reference Range:
Reference Range Not Established
Critical Ranges:
Test Comments:
Methodology:
Chromosome Analysis
Clinical Significance:
Cytogenetic analysis used to determine chromosomal abnormalities important in diagnosis of hematologic malignancies, disease monitoring, and response to certain treatments
Documentation:
Custom Panel:
No
PRODUCTION SCHEDULE
Turn Around Time:
5 to 7 days
Sites Performed:
GenPath Diagnostics
Other Testing Facility:
to BioReference Laboratory
PHL Test Code:
OCHRA
EPIC Test Code:
LAB3233
Send Out Test Code:
J948-1
Alternate Test Names:
Cancer Cytogenetics Karyotype; Chrom-ONC BM/PB; Cytogenetics; Karyotype
Included Tests:
CPT Coding:
88237, 88262, 88291